Palomo Bravo A, Prieto Bonilla R, Bardan Rebollar D, Lopez-Jaime F, Fernandez-Bello I
Clin Case Rep. 2024; 12(8):e9312.
PMID: 39139619
PMC: 11319222.
DOI: 10.1002/ccr3.9312.
Lemons R, Wang M, Curtin J, Lepatan L, Male C, Peyvandi F
TH Open. 2024; 8(1):e155-e163.
PMID: 38532939
PMC: 10965291.
DOI: 10.1055/s-0044-1781466.
Sherman A, Bertolini T, Arisa S, Herzog R, Kaczmarek R
Res Pract Thromb Haemost. 2024; 7(8):102248.
PMID: 38193070
PMC: 10772885.
DOI: 10.1016/j.rpth.2023.102248.
Tran D, Benson C, Boice J, Chitlur M, Dunn A, Escobar M
Expert Rev Hematol. 2023; 16(sup1):19-37.
PMID: 36920859
PMC: 10020869.
DOI: 10.1080/17474086.2023.2171981.
Gualtierotti R, Pasca S, Ciavarella A, Arcudi S, Giachi A, Garagiola I
Pharmaceuticals (Basel). 2022; 15(10).
PMID: 36297295
PMC: 9611302.
DOI: 10.3390/ph15101183.
Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction.
Sun J, Chen X, Chai Z, Niu H, Dobbins A, Nichols T
Front Med (Lausanne). 2022; 9:880763.
PMID: 35991645
PMC: 9388760.
DOI: 10.3389/fmed.2022.880763.
Immune complications and their management in inherited and acquired bleeding disorders.
Arruda V, Lillicrap D, Herzog R
Blood. 2022; 140(10):1075-1085.
PMID: 35793465
PMC: 9461471.
DOI: 10.1182/blood.2022016530.
International consensus recommendations on the management of people with haemophilia B.
Hart D, Matino D, Astermark J, Dolan G, dOiron R, Hermans C
Ther Adv Hematol. 2022; 13:20406207221085202.
PMID: 35392437
PMC: 8980430.
DOI: 10.1177/20406207221085202.
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors.
Shapiro A, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Eichler H
Blood Adv. 2022; 6(11):3422-3432.
PMID: 35290453
PMC: 9198939.
DOI: 10.1182/bloodadvances.2021006403.
Inhibitor in Congenital Factor VII Deficiency; a Rare but Serious Therapeutic Challenge-A Systematic Literature Review.
Ramezanpour N, Zaker F, Biswas A, Dorgalaleh A
J Clin Med. 2021; 10(2).
PMID: 33435610
PMC: 7827513.
DOI: 10.3390/jcm10020211.
Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.
Chan A, Alamelu J, Barnes C, Chuansumrit A, Garly M, Meldgaard R
Res Pract Thromb Haemost. 2020; 4(7):1101-1113.
PMID: 33134776
PMC: 7590314.
DOI: 10.1002/rth2.12412.
Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors.
Brackmann H, Schramm W, Oldenburg J, Cano V, Turecek P, Negrier C
Hamostaseologie. 2020; 40(5):606-620.
PMID: 32717751
PMC: 7772007.
DOI: 10.1055/a-1159-4273.
Immunogenicity of Protein Therapeutics: A Lymph Node Perspective.
Fu K, March K, Alexaki A, Fabozzi G, Moysi E, Petrovas C
Front Immunol. 2020; 11:791.
PMID: 32477334
PMC: 7240201.
DOI: 10.3389/fimmu.2020.00791.
Hemophilia management: Huge impact of a tiny difference.
Kloosterman F, Zwagemaker A, Abdi A, Gouw S, Castaman G, Fijnvandraat K
Res Pract Thromb Haemost. 2020; 4(3):377-385.
PMID: 32211572
PMC: 7086468.
DOI: 10.1002/rth2.12314.
Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study.
Male C, Andersson N, Rafowicz A, Liesner R, Kurnik K, Fischer K
Haematologica. 2020; 106(1):123-129.
PMID: 31919092
PMC: 7776246.
DOI: 10.3324/haematol.2019.239160.
Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.
Miller C
Haemophilia. 2018; 24(2):186-197.
PMID: 29446525
PMC: 6033270.
DOI: 10.1111/hae.13424.
[Immune tolerance induction in a case of hemophilia B with inhibitor with prothrombin complex concentrate and rituximab].
Xue F, Liu W, Cheng Y, Liu X, Huang Y, Fu R
Zhonghua Xue Ye Xue Za Zhi. 2017; 38(9):749-753.
PMID: 29081190
PMC: 7348358.
DOI: 10.3760/cma.j.issn.0253-2727.2017.09.004.
Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells.
Wang X, Herzog R, Byrne B, Kumar S, Zhou Q, Buchholz C
Mol Ther Methods Clin Dev. 2017; 5:76-82.
PMID: 28480307
PMC: 5415320.
DOI: 10.1016/j.omtm.2017.03.005.
Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX.
Rocino A, Franchini M, Coppola A
J Clin Med. 2017; 6(4).
PMID: 28420167
PMC: 5406778.
DOI: 10.3390/jcm6040046.
Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.
Boylan B, Rice A, Neff A, Manco-Johnson M, Kempton C, Miller C
J Thromb Haemost. 2016; 14(10):1931-1940.
PMID: 27501440
PMC: 5083216.
DOI: 10.1111/jth.13438.